Exelixis Announces Webcasts of Upcoming Investor Conference Presentations Exelixis Inc.

Exelixis, Inc. announced today that Michael Morrissey, PhD, the company’s president and chief executive officer, will present at two upcoming investor conferences. 

Morgan Stanley Global Healthcare Conference: Exelixis’ presentation will take place at 10:20 a.m. EDT on Tuesday, September 13, 2011, in New York.

UBS Global Life Sciences Conference: Exelixis’ presentation will take place at 8:30 a.m. EDT on Monday, September 19, 2011, in New York.

During each presentation, Dr. Morrissey will provide a general business update, review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer, and discuss the pivotal trial plans and regulatory strategy for the compound.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs.